PH12022552084A1 - Vaccine against african swine fever virus infection - Google Patents

Vaccine against african swine fever virus infection

Info

Publication number
PH12022552084A1
PH12022552084A1 PH1/2022/552084A PH12022552084A PH12022552084A1 PH 12022552084 A1 PH12022552084 A1 PH 12022552084A1 PH 12022552084 A PH12022552084 A PH 12022552084A PH 12022552084 A1 PH12022552084 A1 PH 12022552084A1
Authority
PH
Philippines
Prior art keywords
swine fever
african swine
fever virus
virus infection
vaccine against
Prior art date
Application number
PH1/2022/552084A
Other languages
English (en)
Inventor
Simon Davis
Linda Dixon
Shinji Ikemizu
Yuan Jenq Lui
Anusyah Rathakrishnan
Ana Reis
Original Assignee
Univ Kumamoto
The Chancellor Masters And Scholars Of The Univ Of Oxford
The Pirbright Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2003292.6A external-priority patent/GB202003292D0/en
Priority claimed from GBGB2003289.2A external-priority patent/GB202003289D0/en
Priority claimed from GBGB2005880.6A external-priority patent/GB202005880D0/en
Priority claimed from GBGB2005878.0A external-priority patent/GB202005878D0/en
Priority claimed from GBGB2013541.4A external-priority patent/GB202013541D0/en
Application filed by Univ Kumamoto, The Chancellor Masters And Scholars Of The Univ Of Oxford, The Pirbright Inst filed Critical Univ Kumamoto
Publication of PH12022552084A1 publication Critical patent/PH12022552084A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation
    • C12N2710/12062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PH1/2022/552084A 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection PH12022552084A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB2003292.6A GB202003292D0 (en) 2020-03-06 2020-03-06 Vaccine
GBGB2003289.2A GB202003289D0 (en) 2020-03-06 2020-03-06 Vaccine
GBGB2005880.6A GB202005880D0 (en) 2020-04-22 2020-04-22 Vaccine
GBGB2005878.0A GB202005878D0 (en) 2020-04-22 2020-04-22 Vaccine
GBGB2013541.4A GB202013541D0 (en) 2020-08-28 2020-08-28 Vaccine
PCT/GB2021/050562 WO2021176236A1 (en) 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection

Publications (1)

Publication Number Publication Date
PH12022552084A1 true PH12022552084A1 (en) 2024-02-26

Family

ID=74870840

Family Applications (2)

Application Number Title Priority Date Filing Date
PH1/2022/552084A PH12022552084A1 (en) 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection
PH1/2022/552086A PH12022552086A1 (en) 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
PH1/2022/552086A PH12022552086A1 (en) 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection

Country Status (13)

Country Link
US (3) US20240293525A1 (cg-RX-API-DMAC7.html)
EP (3) EP4114454A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023516713A (cg-RX-API-DMAC7.html)
KR (2) KR20230013017A (cg-RX-API-DMAC7.html)
CN (3) CN116133680A (cg-RX-API-DMAC7.html)
AU (2) AU2021231402A1 (cg-RX-API-DMAC7.html)
BR (2) BR112022016893A8 (cg-RX-API-DMAC7.html)
CA (2) CA3170058A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002412A1 (cg-RX-API-DMAC7.html)
CO (2) CO2022014152A2 (cg-RX-API-DMAC7.html)
MX (2) MX2022010372A (cg-RX-API-DMAC7.html)
PH (2) PH12022552084A1 (cg-RX-API-DMAC7.html)
WO (3) WO2021176234A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201910794D0 (en) * 2019-07-29 2019-09-11 Pirbright Inst Vaccine
EP4565269A2 (en) * 2022-08-04 2025-06-11 Malcolm, Thomas Dominant negative antigen approach for prophylactic and post-infection treatment of swine against african swine fever virus
WO2024057048A1 (en) * 2022-09-12 2024-03-21 Consejo Superior De Investigaciones Científicas Attenuated african swine fever virus and use thereof in vaccine compositions
CN120936878A (zh) * 2022-11-22 2025-11-11 马德里黄金标准诊断公司 用于区分感染asfv与asfv疫苗接种的动物的方法
CN120897756A (zh) * 2022-11-22 2025-11-04 英特维特国际股份有限公司 减毒非洲猪瘟病毒及其在疫苗组合物中的用途
CN117224669B (zh) * 2023-07-31 2024-07-30 中国农业科学院兰州兽医研究所 非洲猪瘟病毒mgf360-21r蛋白作为免疫诱导剂或者佐剂的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015091322A1 (en) * 2013-12-18 2015-06-25 Boehringer Ingelheim Vetmedica Gmbh Cd2 deficient african swine fever virus as live attenuated or subsequently inactivated vaccine against african swine fever in mammals
GB201410971D0 (en) * 2014-06-19 2014-08-06 Pirbright Inst The Vaccine
US9528094B2 (en) * 2014-11-10 2016-12-27 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated African swine fever virus vaccine based in the deletion of MGF genes
CN110551695A (zh) * 2019-08-14 2019-12-10 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 非洲猪瘟病毒四基因缺失弱毒株及其应用

Also Published As

Publication number Publication date
US20230117978A1 (en) 2023-04-20
WO2021176234A1 (en) 2021-09-10
BR112022016891A2 (pt) 2023-01-24
CL2022002412A1 (es) 2023-03-03
CN115397463A (zh) 2022-11-25
CN115605223A (zh) 2023-01-13
CL2022002416A1 (es) 2023-03-03
WO2021176235A1 (en) 2021-09-10
JP2023516709A (ja) 2023-04-20
US20230124042A1 (en) 2023-04-20
EP4114453A1 (en) 2023-01-11
CO2022014256A2 (es) 2022-12-30
KR20230013016A (ko) 2023-01-26
WO2021176236A1 (en) 2021-09-10
MX2022010372A (es) 2023-01-19
JP2023516713A (ja) 2023-04-20
EP4114455A1 (en) 2023-01-11
MX2022010373A (es) 2023-01-19
BR112022016893A8 (pt) 2023-02-28
KR20230013017A (ko) 2023-01-26
CA3170043A1 (en) 2021-09-10
AU2021231402A1 (en) 2022-11-03
AU2021229654A1 (en) 2022-11-03
US20240293525A1 (en) 2024-09-05
BR112022016893A2 (pt) 2023-01-24
CO2022014152A2 (es) 2023-02-16
PH12022552086A1 (en) 2023-11-20
CA3170058A1 (en) 2021-09-10
EP4114454A1 (en) 2023-01-11
CN116133680A (zh) 2023-05-16

Similar Documents

Publication Publication Date Title
MX2022010372A (es) Vacuna contra la infeccion por el virus de la peste porcina africana.
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
BR112022014808A2 (pt) Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
EA202193251A1 (ru) Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций
EP4104854A3 (en) Multivalent vaccines for rabies virus and coronaviruses
PH12021552736A1 (en) A subunit vaccine for treatment or prevention of a respiratory tract infection
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
MX382566B (es) Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2019003682A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
MX2021005345A (es) Composiciones y metodos.
MX2022000879A (es) Vacuna viral terapeutica.
MX2018010958A (es) Vacuna para virus de zika atenuado vivo.
PH12020551944A1 (en) Reverse peptide vaccine
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
MX2023012368A (es) Vacuna de virus.
PH12015501721A1 (en) Porcine parvovirus 5b, methods of use and vaccine
ZA202309368B (en) Lentiviral vector, lentiviral particle for treating hepatitis b and its preparation method and application thereof
EA201401044A1 (ru) Модифицированный вирус болезни марека и вакцины на его основе
PH12021550987A1 (en) Anti-rabies monoclonal antibodies and cocktail thereof
RU2016114713A (ru) Способы и композиции для лечения s. equi инфекции
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними
ZA202309263B (en) Vaccines for the treatment and prevention of zoonotic infections